Peptide Science · Regeneration · Recovery
BPC-157 & GHK-Cu:
The Regenerative Stack
the Wellness World Is Talking About
What leading voices in peptide science — from Stanford labs to independent podcasts — are saying about the synergy between two of the most studied compounds in regenerative research.
There is a moment, somewhere in the growing literature on peptide science, where two compounds keep appearing side by side. Not by coincidence, and not by marketing — but because the biology seems to demand it. BPC-157 and GHK-Cu operate through fundamentally different mechanisms, yet when examined closely, they trace a near-perfect arc through the same goal: meaningful, multi-layered tissue regeneration.
In recent years, a cluster of researchers, educators, and performance specialists have begun articulating why this pairing matters. Their perspectives — drawn from animal studies, clinical observation, and years of hands-on protocol work — offer one of the most coherent frameworks for understanding what these compounds may do, and why the combination appears to produce something greater than the sum of its parts.
This article brings those voices together, explores the underlying science, and explains why BPC-157 and GHK-Cu have become two of the most discussed compounds in the global peptide conversation.
A note on research status
Both BPC-157 and GHK-Cu are research peptides. The majority of the evidence base for BPC-157 comes from animal studies — predominantly in rodent models — alongside a substantial body of in vitro research. GHK-Cu has a longer history of human cosmetic and dermatological use, with a growing gene expression literature. Neither compound is licensed as a medicinal product in the UK or EU for systemic use in humans. All content here is educational. Nothing in this article constitutes medical advice. Always consult a qualified healthcare professional before considering any peptide protocol.
The Voices Shaping the Conversation
Understanding the state of BPC-157 and GHK-Cu requires understanding who is discussing them — and with what degree of rigour. Below are five individuals whose work has shaped how practitioners and enthusiasts approach these compounds.
Dean Henry
Founder, DN Research (UK) · Health Entrepreneur
A former competitive athlete whose career-ending injury led him into a decade of work at the intersection of functional medicine and peptide science. Henry founded DN Research in the UK and UAE Peptides LLC, and his companies supply clinicians and practitioners across the UK, EU, and Middle East. He is widely recognised for translating complex peptide science into accessible, protocol-driven frameworks, with a particular focus on BPC-157 for recovery and a range of compounds for longevity.
Andrew Huberman, PhD
Professor of Neurobiology, Stanford School of Medicine
Host of the Huberman Lab podcast, one of the most widely followed science communication platforms in the world. In a landmark April 2024 episode on peptide therapeutics, Huberman provided what many consider the most thorough public analysis of BPC-157 to date — examining its mechanisms, the unusual gap between its rich animal literature and lack of formal human trials, its angiogenic activity via VEGF, and the considerations that should inform anyone thinking about its use.
Paul Bakhtiar, MBA
Peptide Protocol Specialist · Podcast Contributor
A peptide industry strategist and educator with a background spanning sports nutrition, wellness clinics, and performance medicine. Bakhtiar has appeared on the Peptide of the Week podcast to break down synergistic stacks — including the "Wolverine" and "Glow" protocols — and advises clinics and med-spas on evidence-informed peptide integration. His work focuses on how complementary stacks can be structured to address multiple phases of the healing cascade.
JD Denham
Podcast Host · Performance Optimisation Advocate
Co-host of Peptide of the Week and host of The Iron Perspective podcast, Denham has become one of the most listened-to independent voices in the peptide education space. Drawing on personal experience across more than fifteen surgeries and years of performance training, he has a particular focus on BPC-157 for tendon and ligament recovery and the Glow Stack (BPC-157 + TB-500 + GHK-Cu) for comprehensive regenerative support. His approach: first-hand experience, patient data, and results seen consistently.
William T. Haas
Podcast Host · Peptide Educator
Co-host of Peptide of the Week alongside JD Denham, Haas brings a complementary perspective on long-term peptide use, cycling strategies, and intelligent stacking. He has discussed GHK-Cu extensively — including its role in hair restoration, collagen remodelling, and as a key differentiator in the Glow Stack versus the foundational Wolverine (BPC-157 + TB-500) protocol. His framing of GHK-Cu as the "anti-ageing layer" that transforms a recovery stack into a longevity protocol has resonated widely in the community.
BPC-157: Body Protection Compound
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide of 15 amino acids, derived from a sequence found naturally in gastric juice. It was first identified and studied by Professor Predrag Sikirić and his team at the University of Zagreb, where it has been the subject of hundreds of preclinical studies over three decades.
Its original context was gastrointestinal: something within the stomach's own protective chemistry appeared to also orchestrate repair. What researchers gradually discovered was far broader in scope.
"BPC-157 encourages cellular turnover and new blood supply through the promotion of angiogenesis. It can exit the gut — but how it gets trafficked to particular sites of injury still isn't fully understood."
Andrew Huberman, PhD — Huberman Lab Podcast, April 2024Huberman's framing captures the essential paradox of BPC-157: enormous animal literature, genuine clinical interest, and a mechanism that remains only partially characterised in humans. He described an unusual circumstance — potentially hundreds of thousands of people using a compound for which robust human trial data remains essentially absent.
His own personal experience was notable. Describing a longstanding L5 spinal compression that had not responded to physical therapy, Huberman revealed that two subcutaneous injections of BPC-157 resolved his pain. He was careful to frame this as anecdata — but it is the kind of anecdata that accumulates across a community and demands formal investigation.
Mechanisms: What the Research Shows
The preclinical evidence base for BPC-157 is extensive. The core mechanisms are reasonably well characterised at the animal and cellular level:
| Mechanism | Description | Relevance |
|---|---|---|
| eNOS Activation | BPC-157 upregulates endothelial nitric oxide synthase activity at injury sites, improving local blood flow and vascular tone | Vascular repair |
| VEGF Signalling | Promotes vascular endothelial growth factor expression, driving the formation of new blood vessels (angiogenesis) at sites of tissue damage | Angiogenesis |
| Fibroblast Migration | Accelerates the recruitment of fibroblasts — the cells responsible for synthesising collagen — to wound sites | Collagen production |
| GH Receptor Upregulation | Increases growth hormone receptor density at injury sites, sensitising tissue to circulating GH. A potential benefit for recovery — and a consideration for those with cancer history | Repair signalling |
| Anti-inflammatory Modulation | Reduces pro-inflammatory cytokine activity and modulates NF-κB pathways — without completely suppressing the inflammatory signal needed for repair | Inflammation control |
| Gut Mucosal Protection | Restores intestinal barrier integrity, supports tight junction repair, and demonstrates cytoprotective effects in the GI tract | Gut health |
As Dean Henry has articulated across his educational work, the striking feature of BPC-157 is its apparent versatility across tissue types. Unlike most growth factors — which require carrier molecules and degrade rapidly — BPC-157 is stable in gastric juice, can be taken orally or injected, and has demonstrated activity across muscle, tendon, ligament, bone, and gut in animal models. It is this breadth that makes it so difficult to characterise in a simple mechanism, and so compelling as a research subject.
Huberman's Protocol Framework
While Huberman was careful to note the absence of rigorous human data, he summarised the dosing approach used in the research and biohacking communities — emphasising cycling as a key safety and efficacy principle.
BPC-157 — Community Protocol Reference (Educational Only)
GHK-Cu: The Copper Tripeptide
If BPC-157 is the injury responder — the compound that drives vascular repair and calls the cellular workforce to the wound site — then GHK-Cu is the architect that follows: remodelling the matrix, organising collagen, and resetting the tissue environment toward something more youthful and resilient.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) was discovered in 1973 by biochemist Loren Pickart, in circumstances that sound almost too elegant for science. Pickart was studying aged liver tissue and noticed that when older liver cells were cultured in blood plasma from younger donors, they began synthesising proteins characteristic of far younger tissue. Something in the younger blood was resetting them. After four years of investigation, he isolated the active factor: a tiny tripeptide of three amino acids — glycine, histidine, lysine — bound to a copper ion.
"GHK-Cu is a copper peptide that naturally occurs in human plasma at levels of around 200 ng/ml at age 20 — but drops to just 80 ng/ml by age 60. Research reveals it can stimulate collagen production while simultaneously breaking down damaged collagen, remodelling your skin from the inside out."
Jay Campbell · Referencing Biomedical Research International findings on GHK-CuThat decline — from 200 ng/ml in young plasma to 80 ng/ml by sixty — maps with uncomfortable precision onto the slowdown in tissue repair, skin resilience, and wound healing that most people begin to notice from their thirties onward. GHK-Cu is not merely a cosmetic ingredient; it is a biological signal whose natural decline appears to coincide with one of the most visible dimensions of ageing.
What GHK-Cu Does at the Cellular Level
The most striking finding in GHK-Cu research — beyond its well-characterised effects on collagen — is its gene expression data. When GHK was analysed using the Broad Institute's Connectivity Map database, Pickart and Margolina found it induced a 50% or greater change in expression across approximately 31.2% of all human genes — an extraordinary breadth of biological influence for a three-amino-acid peptide.[13] The gene pattern shift was described by researchers as a "genomic reset": expression profiles in aged cells moving back toward those characteristic of younger, healthier tissue.
| Effect | Mechanism | Research Context |
|---|---|---|
| Collagen Synthesis | Stimulates type I and type III collagen production by fibroblasts, while simultaneously activating metalloproteinases to break down damaged or disorganised collagen | Pickart et al., 2015 |
| Decorin Production | Upregulates decorin, a small proteoglycan that organises collagen fibres into structurally sound, parallel arrays — the difference between strong, functional repair and disorganised scar tissue | Collagen architecture |
| Antioxidant Activity | Enhances superoxide dismutase (SOD) and catalase activity, reducing oxidative stress in the cellular environment around wounds | Redox biology |
| Angiogenic Support | Promotes capillary formation at wound sites, complementing BPC-157's angiogenic activity through a distinct copper-mediated pathway | Vascular biology |
| Hair Follicle Support | Stimulates follicle cycling and increases follicle size. Haas and Denham have noted observable results in men and women, including thicker and darker regrowth in some users | Dermatology |
| Skin Elasticity | Research published in the Journal of Cosmetics, Dermatological Sciences and Applications found GHK-Cu formulations produced an 11.8% increase in skin elasticity within 30 days | Clinical observation |
William T. Haas has described GHK-Cu as the compound that transforms a tissue-repair stack into a longevity and aesthetics stack. The base Wolverine protocol (BPC-157 + TB-500) addresses acute repair and systemic healing — but it is GHK-Cu, as the third layer in the Glow stack, that adds what Haas calls "the quality layer": ensuring that what regrows does so with proper structure, better collagen architecture, and a skin and hair response that the first two peptides do not deliver.
The Stacking Rationale: Why These Two Work Together
BPC-157 and GHK-Cu are not redundant. They do not compete. They address different phases of the repair cascade — and this is the core of why peptide educators and clinicians have increasingly advocated for their combined use.
BPC-157 — The First Responder
Angiogenesis · Fibroblast recruitment · Inflammation modulation
Arrives first at the site of injury. Signals the vasculature to grow, brings fibroblasts to the wound, modulates the inflammatory environment without shutting it down entirely. Creates the biological infrastructure that makes healing possible. JD Denham describes it as "the tendon and tissue fixer" — particularly potent for acute musculoskeletal injury, tendonitis, and post-surgical recovery.
GHK-Cu — The Remodeller
Collagen architecture · Matrix remodelling · Gene expression · Anti-ageing
Operates on the extracellular matrix level that BPC-157 does not directly address. Where BPC-157 gets blood flow and cells to the site, GHK-Cu ensures that the collagen laid down is organised and functional — driving decorin synthesis to create structured fibre arrays rather than disorganised scar tissue. Also contributes the skin, hair, and anti-ageing dimensions that distinguish the Glow Stack from a purely injury-focused protocol.
TB-500 (Thymosin Beta-4 Fragment) — Optional Systemic Layer
Cell migration · Systemic distribution · Actin regulation
Many practitioners add TB-500 to form what Denham, Haas, and Bakhtiar call the Glow Stack (BPC-157 + TB-500 + GHK-Cu). TB-500 works by modulating actin — the protein that controls cell movement — enabling healing cells to migrate systemically rather than only locally. The full Glow Stack is BPC-157 handling the injury site, TB-500 mobilising the repair workforce across the body, and GHK-Cu ensuring the quality of what is rebuilt.
As Paul Bakhtiar has described it in his work on the Wolverine and Glow protocols: these three peptides are "non-overlapping pathways." BPC-157 modulates nitric oxide signalling. TB-500 modulates actin dynamics. GHK-Cu modulates the copper-mediated extracellular matrix. Each one is doing something the others cannot. The synergy is not theoretical — it is mechanistic.
"One plus one doesn't equal two — it equals four. The real value of peptide therapy is not in individual peptides but in how they are combined."
Dr. Craig Koniver — Huberman Lab Podcast (via Huberman interview)Specific Applications: Who Is Using These, and For What
Musculoskeletal Recovery and Injury
This is where BPC-157 has its deepest evidence base and its most vocal community of users. The University of Zagreb studies — still the most substantial single body of work on this compound — include models of tendon transection, ligament damage, muscle tears, and bone fractures. In each model, BPC-157 consistently accelerated repair and improved tissue quality.
JD Denham, who describes BPC-157 as "Will's number one pick after fifteen-plus surgeries," frames the compound's tendon-specific effects as its single most compelling application. He and Haas have discussed the characteristic experience of high-dose acute protocols: pain initially increasing and then centralising as the healing cascade activates — a sign, they argue, that the compound is working rather than failing.
For joint pain, tendonitis, and post-surgical recovery, the community-standard Wolverine Stack (BPC-157 + TB-500) forms the foundation. The Glow Stack adds GHK-Cu when skin, scar tissue minimisation, and structural matrix quality are also priorities — which is most post-surgical contexts.
Gut Health and Mucosal Repair
BPC-157's origins are gastrointestinal, and its gut effects are among the most consistent in the animal literature. As Dean Henry has discussed across his educational content, BPC-157 supports the re-establishment of intestinal tight junctions, provides cytoprotection across the mucosal lining, and has shown activity in models of colitis, IBS, and leaky gut.
For gut applications, oral BPC-157 (capsule form) is the preferred delivery route — the peptide reaches the intestinal lining directly rather than being absorbed systemically. The dose and cycling logic remains similar, but the route of administration differs fundamentally from musculoskeletal applications.
Skin, Hair, and Anti-Ageing
GHK-Cu carries the aesthetic dimension of these protocols. Its decline with age — from 200 ng/ml to 80 ng/ml between the ages of twenty and sixty — correlates with the visible changes that accompany ageing: thinner skin, reduced elasticity, slower wound healing, and hair loss.
Haas has described GHK-Cu's hair effects as among the most visually striking outcomes observed across their community: thicker, darker regrowth in both men and women, driven by the compound's effects on follicle cycling and follicle size. In skin, GHK-Cu works through two simultaneous actions — stimulating new collagen synthesis while also breaking down damaged, disorganised collagen — effectively remodelling the matrix from within.
This dual action (synthesis and breakdown) is what distinguishes GHK-Cu from simple collagen boosters. It is not merely adding collagen; it is creating the conditions for better-organised, more resilient connective tissue.
Longevity and Systemic Maintenance
JD Denham's full personal protocol — outlined in his Iron Perspective podcast — positions GHK-Cu alongside the Wolverine Stack as part of a continuous longevity-maintenance approach rather than a purely acute intervention. Dean Henry, whose work spans longevity, cognitive enhancement, and metabolic health, situates BPC-157 within a broader anti-ageing framework that includes bioregulators, mitochondrial support, and nootropic compounds.
The case for ongoing, cycled use of BPC-157 and GHK-Cu as maintenance tools — rather than one-time injury interventions — is gaining traction in the longevity space, though it is important to note that the long-term data to support this use simply does not yet exist in humans.
Safety Considerations: What the Evidence Tells Us
Huberman's peptide episode was notable for its explicit risk framing, and it is worth reproducing that framing here.
For BPC-157: The compound is considered relatively safe at the doses discussed above, with no reported lethal dose established in animal models. However, its angiogenic activity — the same mechanism that makes it useful for tissue repair — creates a theoretical concern for anyone with a cancer history or active tumour. BPC-157 drives blood vessel formation; tumours require blood vessel formation to grow. This is not a hypothetical risk and should be taken seriously. Anyone with a personal or family history of cancer should consult a qualified oncologist before any consideration of BPC-157.
For GHK-Cu: The compound has a long and relatively clean safety profile in cosmetic applications, where topical use has been practised for decades. At systemic doses, copper delivery is the primary consideration — the body tightly regulates copper excretion through bile, and toxicity at the doses used in standard protocols is considered unlikely. However, practitioners generally recommend cycling off after 8–12 weeks and obtaining a baseline copper and ceruloplasmin measurement for longer protocols. GHK-Cu is contraindicated in Wilson's Disease (a copper metabolism disorder). As with BPC-157, active cancer or tumour history is a consideration, given that GHK-Cu also promotes angiogenesis.
Sourcing: Huberman was emphatic about this point, and the broader community echoes it. Peptides sourced from unregulated channels are frequently contaminated with lipopolysaccharide (LPS) — a bacterial membrane component that can trigger significant immune responses. Haas has discussed GI distress from low-quality BPC-157 capsules as a specific red flag. Purity verification through HPLC and mass spectrometry, with batch-level certificates of analysis, is the minimum standard for any serious engagement with these compounds.
On Sourcing and Purity
Velyx works exclusively with suppliers who provide independently verified purity data at the batch level. The conversation around sourcing — raised by Huberman, Denham, Henry, and virtually every credible voice in this space — is not a secondary concern. It is the primary concern. The safety profile of any peptide is only as reliable as the purity of the material used.
The State of the Science: Where We Are in 2026
The peptide regulatory landscape shifted significantly in late 2023 when the FDA placed BPC-157 on its Category 2 restricted list in the United States, removing it from the compounding pharmacy pathway. In early 2026, HHS Secretary RFK Jr. publicly stated that BPC-157 and thirteen other restricted peptides were expected to move back to Category 1 — but as of writing, the formal FDA update has not been published. In the UK and EU, BPC-157 exists in a research context, without the licensed medicinal product pathway that would govern clinical prescription use.
GHK-Cu occupies a different regulatory space. Its long history in cosmetics means that topical formulations are widely available and legally unambiguous. Systemic use — subcutaneous or intravenous — falls into the same research territory as BPC-157 in most jurisdictions.
The scientific community's interest in both compounds continues to grow. The University of Zagreb's BPC-157 research programme remains active. GHK-Cu's gene expression findings have attracted interest from researchers well outside the wound healing space. The Glow Stack and its variants have entered clinical conversation at a number of regenerative medicine centres and aesthetic clinics.
What remains absent — and what the entire community acknowledges — is the rigorous, large-scale, randomised controlled trial data that would move these compounds from "compelling preclinical evidence and extensive anecdata" to "established human therapeutics." That work has not been done. Whether it will be done — given the challenges of funding trials for compounds that cannot be easily patented — remains an open question.
"It's pretty unusual to have so much quality animal literature on BPC-157, and such a dearth of formal, rigorous exploration in humans. The anecdata are enticing — but there are real risks, and real unknowns."
Andrew Huberman, PhD — Huberman Lab Podcast, April 2024In Summary
BPC-157 and GHK-Cu represent two distinct but complementary mechanisms in the regenerative toolkit. BPC-157 is the first responder: driving angiogenesis, recruiting fibroblasts, modulating inflammation, and creating the vascular and cellular infrastructure for repair. GHK-Cu is the architect: organising the collagen matrix, reducing oxidative stress, stimulating gene expression related to tissue remodelling, and — with its age-related decline — potentially representing one of the most tractable targets in anti-ageing biochemistry.
The voices bringing these compounds to a wider audience — Dean Henry, Andrew Huberman, Paul Bakhtiar, JD Denham, and William T. Haas — are united not just in their interest in the compounds themselves, but in their insistence on a consistent set of principles: start conservative on dosing, cycle off consistently, source with rigour, and always consult a qualified healthcare professional before proceeding.
The science is compelling. The evidence base, while predominantly preclinical, is substantial. The human experience is accumulating rapidly. What remains — and what the honest voices in this space consistently return to — is the need for formal human trials that can either validate or qualify what the animal data and the global community of users are increasingly pointing toward.
At Velyx, our role is to track this science, source with integrity, and make these compounds available to the researchers, clinicians, and informed individuals for whom they are relevant — while being honest about what we know, what we don't, and where the evidence currently stands.
References
All peer-reviewed references are cited by PMID where available. Podcast and media sources are cited as primary audio/editorial content. References are numbered in order of first appearance in the article.
[1] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976–983. PMID: 14554204. doi:10.1016/S0736-0266(03)00110-4
[2] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982–989. PMID: 16583442. doi:10.1002/jor.20096
[3] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153–159. PMID: 30915550. doi:10.1007/s00441-019-03016-8
[4] Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Current Pharmaceutical Design. 2018;24(18):1990–2001. PMID: 29879879. doi:10.2174/1381612824666180608101119
[5] Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID: 25419539. PMC: PMC6270854. doi:10.3390/molecules191119066
[6] Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Sports Health. 2025. PMID: 40756949. doi:10.1177/15563316251355551
[7] Huberman AD. Benefits & Risks of Peptide Therapeutics for Physical & Mental Health. Huberman Lab Podcast. Episode released 1 April 2024. Available at: hubermanlab.com [Accessed May 2026]
[8] Pickart L. PhD Thesis. University of California, San Francisco, 1973. [Original isolation of GHK from human plasma albumin]
[9] Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. PMID: 26236730. PMC: PMC4508379. doi:10.1155/2015/648108
[10] Wikipedia contributors. Copper peptide GHK-Cu. Wikipedia, The Free Encyclopedia. Available at: en.wikipedia.org/wiki/Copper_peptide_GHK-Cu [Accessed May 2026] — citing original plasma level data: ~200 ng/mL at age 20 declining to ~80 ng/mL by age 60.
[11] Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Letters. 1988;238(2):343–346. PMID: 3169264. doi:10.1016/0014-5793(88)80509-X
[12] Pickart L, Margolina A. Skin and hair regenerative and protective actions of copper peptides. MDPI Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029 — citing clinical skin elasticity studies from 1985 onwards.
[13] Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520. PMC: PMC6073405. doi:10.3390/ijms19071987 — Broad Institute Connectivity Map analysis: GHK induces ≥50% expression change in 31.2% of human genes.
[14] Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biochemistry Insights. 2014;7:BCI.S12598. PMC: free article. [Connectivity Map colon cancer gene reversal data: 70% of 54 overexpressed genes reversed by GHK from 1,309 bioactive molecules tested.]
[15] Pickart L, Vasquez-Soltero JM, Margolina A. The human skin remodeling peptide GHK induces anti-cancer expression of numerous caspase, growth regulatory, and DNA repair genes. Journal of Analytical Oncology. 2014;3(2):79–87.
[16] Pickart L, Margolina A. The effect of the human plasma molecule GHK-Cu on stem cell actions and expression of relevant genes. OBM Geriatrics. 2018;2(3):009. doi:10.21926/obm.geriatr.1803009
[17] Badenhorst T, Svirskis D, Merrilees M. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science. 2016;4(3). [11.8% elasticity improvement finding at 30 days referenced in Glow Stack literature.]
[18] Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155–1161. PMID: 20225319. doi:10.1002/jor.21107
[19] Denham JD, Haas WT. Peptide of the Week: BPC-157 — Healing from the Inside Out. Peptide of the Week Podcast. Episode released January 2026. Available at: Spotify/Apple Podcasts [Accessed May 2026]
[20] Denham JD, Haas WT, Bakhtiar P. Peptide of the Week: Wolverine Protocol, Glow Stack & KLOW Blend. Peptide of the Week Podcast. Episode available at: creators.spotify.com/pod/profile/peptide-of-the-week [Accessed May 2026]
[21] Denham JD. My Full Peptide Protocol. The Iron Perspective with JD Denham Podcast. Episode 47, released 26 January 2026. Available at: Apple Podcasts [Accessed May 2026]
[22] Henry D. Peptides, Health Optimization, BPC 157 and Longevity. Yorick's TV Show Podcast. Episode 13, released 17 May 2024. Available at: Spotify / Podbean [Accessed May 2026]
[23] Henry D. Biography. Bioniq Lab. Available at: bioniqlab.com/dean-henry/ [Accessed May 2026]
[24] Koniver C. [Interview with Andrew Huberman] Peptide & Hormone Therapies for Health, Performance & Longevity. Huberman Lab Podcast. 2024. "One plus one doesn't equal two — it equals four." Available at: hubermanlab.com [Accessed May 2026]
[25] Sikiric P, Seiwerth S, Grabarevic Z, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2012. PMID: PMC8275860 review. [Wound healing overview, intestinal barrier cytoprotection data.]
[26] Fastlifehacks.com. Andrew Huberman's Peptide List — Peptides He's Taken & Discussed. Updated May 2026. Available at: fastlifehacks.com/andrew-huberman-peptides/ [Accessed May 2026] — secondary source summarising Huberman podcast content including FDA regulatory timeline.